Paclitaxel

For research use only.

Catalog No.S1150 Synonyms: NSC 125973, PTX, Taxol, Onxal

184 publications

Paclitaxel Chemical Structure

CAS No. 33069-62-4

Paclitaxel (NSC 125973, PTX, Taxol, Onxal) is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Paclitaxel has been cited by 184 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Paclitaxel (NSC 125973, PTX, Taxol, Onxal) is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
Targets
Microtubule (human endothelial cells) [1]
0.1 pM
In vitro

Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. [1] In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. [2] Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PRdGlEPTB;MD6wNFAzQDdizszN MVLTRW5ITVJ?
LC-2-ad NFr4V4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTYV|NHUUN3ME2wMlAxODNzNzFOwG0> NHzq[VBUSU6JRWK=
RL95-2 NEP5NlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTBwMECwOlY5KM7:TR?= NUDMTFJiW0GQR1XS
MZ1-PC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfkXnBuUUN3ME2wMlAxODd{OTFOwG0> MkHGV2FPT0WU
TE-8 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMECxNVch|ryP M2HJe3NCVkeHUh?=
SW954 NGjLPGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7nco1LUUN3ME2wMlAxOTF7IN88US=> NF\Gdo9USU6JRWK=
TE-11 MlzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjJfGNKSzVyPUCuNFAyOjNizszN Mm\4V2FPT0WU
PSN1 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC5UXJNUUN3ME2wMlAxOTNizszN MV7TRW5ITVJ?
MOLT-4 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3jU2lKSzVyPUCuNFAyPDlizszN NF;0dWhUSU6JRWK=
697 MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLRTWM2OD1yLkCwNVUh|ryP M2HnSXNCVkeHUh?=
ETK-1 MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwMECxOVIh|ryP NHzH[VVUSU6JRWK=
TE-10 NHjB[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\CTWM2OD1yLkCwNVU1KM7:TR?= Mn24V2FPT0WU
HUTU-80 NYq3Om4yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XyXmlEPTB;MD6wNFE3QCEQvF2= NXXnW49WW0GQR1XS
NTERA-S-cl-D1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTBwMECyNFkh|ryP M4DQc3NCVkeHUh?=
MFH-ino M4DwRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;pV4plUUN3ME2wMlAxOjZ6IN88US=> MUPTRW5ITVJ?
IA-LM M2XCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\jTWM2OD1yLkCwNlgh|ryP NVX2TGc{W0GQR1XS
MC116 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:zTWM2OD1yLkCwNlg6KM7:TR?= NIDrWGRUSU6JRWK=
RKO NHzz[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPQUFVoUUN3ME2wMlAxOjl6IN88US=> MWnTRW5ITVJ?
MRK-nu-1 Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLITWM2OD1yLkCwNlk6KM7:TR?= M1[1c3NCVkeHUh?=
VA-ES-BJ MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMECzJO69VQ>? Mn\PV2FPT0WU
KALS-1 M2G5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmWzTWM2OD1yLkCwN|A5KM7:TR?= NH\VWG9USU6JRWK=
BB30-HNC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXQVIZKSzVyPUCuNFA{OTRizszN MWfTRW5ITVJ?
ACN NWWyZYNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PLOWlEPTB;MD6wNFMyPiEQvF2= NI\2fYRUSU6JRWK=
TE-9 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjvXWFIUUN3ME2wMlAxOzJ4IN88US=> NX3UfmFpW0GQR1XS
SIG-M5 MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TGO2lEPTB;MD6wNFMzPyEQvF2= NXfCV3RtW0GQR1XS
no-10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMECzOlIh|ryP NE\TdGFUSU6JRWK=
EW-1 NYXKVmhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TqO2lEPTB;MD6wNFM4OSEQvF2= MXfTRW5ITVJ?
SK-LMS-1 NXuwO|hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHiTWM2OD1yLkCwOFAyKM7:TR?= NX;kTXZiW0GQR1XS
GT3TKB NFzFd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjnTWM2OD1yLkCwOFM1KM7:TR?= NULSeHZGW0GQR1XS
ES4 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\jcmlIUUN3ME2wMlAxPDR7IN88US=> NIjJT2lUSU6JRWK=
IMR-5 NIjQNFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTaTWM2OD1yLkCwOFUh|ryP MV3TRW5ITVJ?
NCI-H1648 M3\XeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmCxTWM2OD1yLkCwOFY6KM7:TR?= NHXRRVNUSU6JRWK=
MV-4-11 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7se5NKSzVyPUCuNFA1PzVizszN MlzhV2FPT0WU
SK-UT-1 NIrMSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrFRosxUUN3ME2wMlAxPDhizszN M3nuV3NCVkeHUh?=
NB13 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEC0PVEh|ryP MXXTRW5ITVJ?
DJM-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjaTWM2OD1yLkCwOVMh|ryP M4X6eXNCVkeHUh?=
ES8 NIDE[pZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\Se3I5UUN3ME2wMlAxPTN6IN88US=> MmXQV2FPT0WU
TE-6 NEW0[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMEC1O{DPxE1? NFTsdIdUSU6JRWK=
KS-1 NHPGdHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\pSG1CUUN3ME2wMlAxPTh{IN88US=> M2XZdHNCVkeHUh?=
TE-1 NWDR[IZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3sUHV7UUN3ME2wMlAxPjB4IN88US=> NVTZZW9SW0GQR1XS
ATN-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TVR2lEPTB;MD6wNFYxQSEQvF2= NYS2b2hrW0GQR1XS
A4-Fuk NHjqZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\uUHNKSzVyPUCuNFA3OTFizszN NH:yUHdUSU6JRWK=
ALL-PO MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjHeYlKSzVyPUCuNFA3OyEQvF2= Ml3oV2FPT0WU
BE-13 NVrpVm54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorDTWM2OD1yLkCwOlM3KM7:TR?= Ml[zV2FPT0WU
KM12 MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEj5RXlKSzVyPUCuNFA3OzdizszN NE\Fe|ZUSU6JRWK=
NOS-1 NYG2bYtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEC2OUDPxE1? M{fkenNCVkeHUh?=
SW962 M2L0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLTTWM2OD1yLkCwOlYzKM7:TR?= Ml6xV2FPT0WU
OCUB-M NI[xXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEC2OlIh|ryP M1fyRXNCVkeHUh?=
NCI-H510A NUOwUHdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vQbmlEPTB;MD6wNFY3PSEQvF2= MYnTRW5ITVJ?
EW-16 NF\GcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXiTWM2OD1yLkCwOlk1KM7:TR?= MlnPV2FPT0WU
KGN NGr3WFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLEWWJKSzVyPUCuNFA4OTJizszN MUHTRW5ITVJ?
LS-411N M3fQNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTRTpo3UUN3ME2wMlAxPzF5IN88US=> M2fEWXNCVkeHUh?=
Becker MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnaTppzUUN3ME2wMlAxPzJizszN NFS5S4RUSU6JRWK=
HC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LYSGlEPTB;MD6wNFczOSEQvF2= MkGzV2FPT0WU
CESS M1XNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITQWZhKSzVyPUCuNFA4OzdizszN MUDTRW5ITVJ?
KURAMOCHI Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TiUWlEPTB;MD6wNFc1QCEQvF2= NYTIWYhPW0GQR1XS
TGBC24TKB MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMEC3OVIh|ryP MVPTRW5ITVJ?
SW982 M{nlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrJWZBKSzVyPUCuNFA4PjZizszN MX;TRW5ITVJ?
HCE-4 NF7SSo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi4TWM2OD1yLkCwO|Y4KM7:TR?= MkfWV2FPT0WU
LOUCY MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L6RWlEPTB;MD6wNFc4PSEQvF2= M{XkcnNCVkeHUh?=
8-MG-BA M3XTbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj3TWM2OD1yLkCwO|k3KM7:TR?= MoDnV2FPT0WU
HT-144 NYPKU5JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHPfpF[UUN3ME2wMlAxQCEQvF2= M4XIdXNCVkeHUh?=
LXF-289 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILIO4FKSzVyPUCuNFA5OThizszN M{LESXNCVkeHUh?=
RS4-11 NGrCNXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn25TWM2OD1yLkCwPFM3KM7:TR?= MkfQV2FPT0WU
DEL NEHKc2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[zR4hjUUN3ME2wMlAxQDR3IN88US=> M3\WXHNCVkeHUh?=
OCI-AML2 MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zHdmlEPTB;MD6wNFg2OiEQvF2= MX3TRW5ITVJ?
CCRF-CEM M4eyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfBO4VKSzVyPUCuNFA5PzFizszN M2[xOnNCVkeHUh?=
A388 M2DmPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMEC4O|Qh|ryP NET5T5RUSU6JRWK=
KNS-42 MoHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHRNJpKSzVyPUCuNFA5QTFizszN NUXlV5Q1W0GQR1XS
OVCAR-4 NUfuOG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHZcFdKSzVyPUCuNFA6ODRizszN NWLpSJJiW0GQR1XS
NCI-H1355 MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwMEC5NVQh|ryP NEHtWXpUSU6JRWK=
BL-70 MlLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy4bVFqUUN3ME2wMlAxQTNizszN MXHTRW5ITVJ?
BL-41 NVHSWnJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwMEC5N|Qh|ryP M4HrPHNCVkeHUh?=
A101D MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX1e2N1UUN3ME2wMlAxQTZizszN MorvV2FPT0WU
HL-60 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHp[pdjUUN3ME2wMlAxQTZ4IN88US=> MVzTRW5ITVJ?
COR-L279 NIDnWVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TpO2lEPTB;MD6wNFk6QSEQvF2= NHvkcXZUSU6JRWK=
NCI-SNU-16 MlKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjsTWM2OD1yLkCxNFA5KM7:TR?= NYftOnYxW0GQR1XS
Calu-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXP6[GRuUUN3ME2wMlAyODF{IN88US=> MlXDV2FPT0WU
SR NGrZZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwMEGwNlYh|ryP M3jvT3NCVkeHUh?=
QIMR-WIL MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH2wcXVKSzVyPUCuNFExOzNizszN NETtTZFUSU6JRWK=
LB647-SCLC NXLocXh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne2TWM2OD1yLkCxNFUyKM7:TR?= MXfTRW5ITVJ?
RPMI-8226 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jveGlEPTB;MD6wNVExOiEQvF2= NXPqWppLW0GQR1XS
SK-PN-DW MoLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMEGxNVIh|ryP M2\mbHNCVkeHUh?=
SF268 M4j1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[yOlk6UUN3ME2wMlAyOTVzIN88US=> M2TJb3NCVkeHUh?=
HD-MY-Z NH2zNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPlTWM2OD1yLkCxNVY{KM7:TR?= Mn7lV2FPT0WU
DOHH-2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnjVGR[UUN3ME2wMlAyOjB|IN88US=> NFf0ZWRUSU6JRWK=
SCC-3 MkLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID0dJNKSzVyPUCuNFEzODRizszN NFexV5VUSU6JRWK=
ST486 NEDOPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfGelFvUUN3ME2wMlAyOjB2IN88US=> MWjTRW5ITVJ?
NALM-6 M{TxN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jrSGlEPTB;MD6wNVIyPCEQvF2= M4XDSnNCVkeHUh?=
NCI-H1436 NILWb4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjGTWM2OD1yLkCxNlMyKM7:TR?= MYXTRW5ITVJ?
KE-37 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETsSoJKSzVyPUCuNFEzOzRizszN M1PRVHNCVkeHUh?=
RPMI-8402 NWjoZXZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq1PWhKSzVyPUCuNFEzPTZizszN MlTGV2FPT0WU
RXF393 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWW0dZBxUUN3ME2wMlAyOjV5IN88US=> M{PlPXNCVkeHUh?=
KARPAS-45 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TFXmlEPTB;MD6wNVI4KM7:TR?= NW\neINXW0GQR1XS
HOP-62 MoLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTzOHdKSzVyPUCuNFEzPzZizszN MkeyV2FPT0WU
ES1 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7RNWxKSzVyPUCuNFEzQDhizszN MUfTRW5ITVJ?
L-363 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMEGzOVEh|ryP NV7ZcZk1W0GQR1XS
GI-1 M4W2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj0WYRKSzVyPUCuNFE{PzNizszN NWrTU2xTW0GQR1XS
CTV-1 NUH5XHJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XB[WlEPTB;MD6wNVQ4QCEQvF2= M2nlVXNCVkeHUh?=
TE-5 M{LiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvOTWM2OD1yLkCxOFk3KM7:TR?= NF;BOXhUSU6JRWK=
SNU-C2B NX\le5JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULyRpZmUUN3ME2wMlAyPDl4IN88US=> MlfjV2FPT0WU
K-562 M2XidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HI[2lEPTB;MD6wNVUyPiEQvF2= NE\teFhUSU6JRWK=
SNB75 M1jJPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwMEG1OEDPxE1? M3PVRnNCVkeHUh?=
MOLT-13 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjiXplKSzVyPUCuNFE3OzdizszN NXjtWIpKW0GQR1XS
LS-123 NY\tW49qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGwNZF5UUN3ME2wMlAyPjZ2IN88US=> M{jvOXNCVkeHUh?=
NCI-SNU-5 NInqbGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTtWlFKSzVyPUCuNFE4ODFizszN MYLTRW5ITVJ?
Daudi NHTFXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMEG3NFgh|ryP NX;aSop{W0GQR1XS
A253 NInEeY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jJN2lEPTB;MD6wNVc{QCEQvF2= MmH0V2FPT0WU
TGBC1TKB M4PZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXsV3FOUUN3ME2wMlAyPzV{IN88US=> Ml\WV2FPT0WU
SJSA-1 MknBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHjTWM2OD1yLkCxO|Y4KM7:TR?= NIT4d|FUSU6JRWK=
NCCIT M1vI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEG3Olkh|ryP MmPXV2FPT0WU
NCI-H69 MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFj3NINKSzVyPUCuNFE4PzhizszN M{DCT3NCVkeHUh?=
SH-4 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMEG4PVUh|ryP MkLuV2FPT0WU
HCC1187 M2PwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3T1S2lEPTB;MD6wNVkzPCEQvF2= NWPsSGFvW0GQR1XS
HCC1599 M1W0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uxUmlEPTB;MD6wNlAzKM7:TR?= MXLTRW5ITVJ?
ONS-76 M4TZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwMEKwN|Yh|ryP M4jIVnNCVkeHUh?=
KU812 M3vidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrJboZKSzVyPUCuNFIxOzlizszN NEjYUHpUSU6JRWK=
ML-2 Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPJVHdKSzVyPUCuNFIxPDdizszN M17uTHNCVkeHUh?=
HCE-T NGHNemNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXjbXpKSzVyPUCuNFIxQTJizszN MmD5V2FPT0WU
NCI-H446 NH\CXG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHsb4xvUUN3ME2wMlAzOTF{IN88US=> NGPDZmlUSU6JRWK=
RPMI-6666 NYXuXZFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\aT4FKSzVyPUCuNFIyPDlizszN M3PoO3NCVkeHUh?=
MOLT-16 M1T4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMEKxOVMh|ryP NV;4b2t4W0GQR1XS
JiyoyeP-2003 NGLvUVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K5eGlEPTB;MD6wNlE4PiEQvF2= MmPxV2FPT0WU
MHH-PREB-1 M3HZemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEKxPVEh|ryP MUnTRW5ITVJ?
MC-CAR NX25e3pFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXUTWM2OD1yLkCyN|I3KM7:TR?= M{T2enNCVkeHUh?=
BC-3 M2S5c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX2wbW52UUN3ME2wMlAzOzR2IN88US=> NFW3PXdUSU6JRWK=
KINGS-1 M3SwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HJe2lEPTB;MD6wNlM2PSEQvF2= MlnlV2FPT0WU
PF-382 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPkTWM2OD1yLkCyN|c5KM7:TR?= NHL3e2FUSU6JRWK=
J-RT3-T3-5 NGL4clVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XiNWlEPTB;MD6wNlM5OyEQvF2= NELF[WxUSU6JRWK=
SF539 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmCyTWM2OD1yLkCyOFAyKM7:TR?= NG[0e3lUSU6JRWK=
LB831-BLC NWP0NG1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37mdmlEPTB;MD6wNlQ5PSEQvF2= MX3TRW5ITVJ?
DMS-114 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLoTWM2OD1yLkCyOVAzKM7:TR?= MoPKV2FPT0WU
LB1047-RCC NILodnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTBwMEK1NUDPxE1? NHrK[49USU6JRWK=
LB771-HNC MnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\jPWlEPTB;MD6wNlU{PCEQvF2= NVzOUJBnW0GQR1XS
BB65-RCC M1\mSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMEK1N|Qh|ryP MlT1V2FPT0WU
BV-173 M3fSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHLTmlKSzVyPUCuNFI2PTRizszN NEDiTIVUSU6JRWK=
ARH-77 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nEcWlEPTB;MD6wNlYxOSEQvF2= M2[3dnNCVkeHUh?=
IST-MEL1 M1;n[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{P2T2lEPTB;MD6wNlYzOyEQvF2= NF;JPVRUSU6JRWK=
NB1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkWzTWM2OD1yLkCyOlg4KM7:TR?= MVzTRW5ITVJ?
EoL-1-cell M2jnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPzTWM2OD1yLkCyOlg5KM7:TR?= MUfTRW5ITVJ?
KY821 M3PUbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PmSGlEPTB;MD6wNlY6PyEQvF2= M3;HSXNCVkeHUh?=
CMK NE\0WpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnVe5ZKSzVyPUCuNFI4OzRizszN NHPRUnZUSU6JRWK=
NCI-H2126 NFjlc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXrNXVbUUN3ME2wMlAzPzZ6IN88US=> MVPTRW5ITVJ?
NCI-H526 MlPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Ox[2lEPTB;MD6wNlg6OSEQvF2= NY\CbZlnW0GQR1XS
COLO-684 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzNOINKSzVyPUCuNFI6ODhizszN MmfKV2FPT0WU
NCI-H747 M2DQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTBwMEK5N|Mh|ryP Ml7BV2FPT0WU
JAR MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnuS5BKSzVyPUCuNFI6PDZizszN MUHTRW5ITVJ?
MEG-01 M4e1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwMEK5O|gh|ryP NXG3cIhIW0GQR1XS
MONO-MAC-6 NVXvWlJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPzTWM2OD1yLkCzNFI{KM7:TR?= M4nHUXNCVkeHUh?=
IST-SL1 M{PncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEOwOFIh|ryP NVruUnY2W0GQR1XS
CPC-N NXznO4hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnUUIJpUUN3ME2wMlA{ODd7IN88US=> Mnm4V2FPT0WU
NCI-H1963 NFTtXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMEOxN|Eh|ryP MnvQV2FPT0WU
K052 MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zuN2lEPTB;MD6wN|I1PyEQvF2= M4LkfXNCVkeHUh?=
KM-H2 NEnze29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMEOzNFch|ryP MoSzV2FPT0WU
TE-12 MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvsTWM2OD1yLkCzN|A6KM7:TR?= M4[xTHNCVkeHUh?=
TK10 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMEOzOVYh|ryP NYnMbXMzW0GQR1XS
NMC-G1 M1PvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nkPWlEPTB;MD6wN|Q2OiEQvF2= NFvS[pNUSU6JRWK=
no-11 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMEO0O|gh|ryP NX\2cFNiW0GQR1XS
NCI-H524 NWnaZmNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX65bHk{UUN3ME2wMlA{PTJ7IN88US=> MojyV2FPT0WU
MHH-CALL-2 M3XHVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvmVmZiUUN3ME2wMlA{PTZ{IN88US=> NID5VppUSU6JRWK=
GB-1 M3K0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEO2JO69VQ>? MVnTRW5ITVJ?
OPM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jnb2lEPTB;MD6wN|Y4OyEQvF2= MV7TRW5ITVJ?
RH-1 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUO2SmJyUUN3ME2wMlA{QDF7IN88US=> M1HNd3NCVkeHUh?=
NCI-H64 NES4[oFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULybINQUUN3ME2wMlA{QDV5IN88US=> M4Wyd3NCVkeHUh?=
EVSA-T NXT4NYw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnu1TWM2OD1yLkCzPVI{KM7:TR?= NIr5[45USU6JRWK=
KARPAS-299 MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17IZWlEPTB;MD6wN|k5KM7:TR?= NVXMVHpoW0GQR1XS
MZ7-mel M4LtOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLUTWM2OD1yLkC0NFQh|ryP M{KzTXNCVkeHUh?=
LB373-MEL-D NVezVYo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LZcmlEPTB;MD6wOFExPSEQvF2= MnLLV2FPT0WU
HEL Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMESxOEDPxE1? MlnjV2FPT0WU
SW872 M3XaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn34TWM2OD1yLkC0NlEh|ryP NX;ReZhxW0GQR1XS
DU-4475 NVjVfllrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jUVmlEPTB;MD6wOFI1PCEQvF2= NG\QdIVUSU6JRWK=
IST-SL2 NEfwb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzFTWM2OD1yLkC0Nlc2KM7:TR?= M{nsUXNCVkeHUh?=
NCI-H82 NFLaXGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3JTWM2OD1yLkC0N|A4KM7:TR?= MoPYV2FPT0WU
LC4-1 NH[3[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPt[mI{UUN3ME2wMlA1OzVzIN88US=> NVPoZ5l7W0GQR1XS
HDLM-2 M2TTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHR[m5SUUN3ME2wMlA1Ozl{IN88US=> MmXWV2FPT0WU
MMAC-SF MojWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\2Z2lEPTB;MD6wOFU{PCEQvF2= M2\MdHNCVkeHUh?=
L-540 NGOxO2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTBwMES2N|kh|ryP MYHTRW5ITVJ?
MZ2-MEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuydGNKSzVyPUCuNFQ4PDJizszN M3fEN3NCVkeHUh?=
LU-134-A NGX5T5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMES3O|Mh|ryP MXzTRW5ITVJ?
UACC-257 NVLsOok2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCwTWM2OD1yLkC0PFQ6KM7:TR?= NYO0PINwW0GQR1XS
NCI-H1581 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XPdmlEPTB;MD6wOFk2OyEQvF2= NXvxR4M5W0GQR1XS
NB17 Mk\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMES5O|kh|ryP NX7BXYJWW0GQR1XS
SBC-1 NF;ITXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXxT|dPUUN3ME2wMlA2ODR{IN88US=> MXPTRW5ITVJ?
TALL-1 M2rKRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTBwMEWwOFUh|ryP NWrKSJp4W0GQR1XS
NCI-H1304 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF2yem1KSzVyPUCuNFUzODhizszN M1PvWXNCVkeHUh?=
NEC8 NFfrU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\aTWM2OD1yLkC1Nlg3KM7:TR?= Ml:wV2FPT0WU
CAL-148 NV\0V4hyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEW0N|kh|ryP MnLuV2FPT0WU
CGTH-W-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonGTWM2OD1yLkC1OFQ6KM7:TR?= NVjN[ZViW0GQR1XS
NCI-H889 M3HrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwMEW1PVIh|ryP MVfTRW5ITVJ?
GR-ST MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwMEW2NlEh|ryP Ml\BV2FPT0WU
KARPAS-422 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjUfZNKSzVyPUCuNFU3PSEQvF2= MlzmV2FPT0WU
RPMI-8866 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTMTWM2OD1yLkC1O|EzKM7:TR?= MYDTRW5ITVJ?
SCLC-21H MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwMEW4PFQh|ryP M4f2NXNCVkeHUh?=
COR-L88 NF3jTJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;pfWFMUUN3ME2wMlA2QTJ5IN88US=> MX3TRW5ITVJ?
LU-139 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fEZWlEPTB;MD6wOVk5PiEQvF2= NVPyfYZzW0GQR1XS
SF126 NGPjUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXQTWM2OD1yLkC2NVM{KM7:TR?= MlrPV2FPT0WU
NCI-H1882 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIThOZdKSzVyPUCuNFY1OjRizszN MmLiV2FPT0WU
EW-24 NF;scWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwME[0PFMh|ryP NHLs[XlUSU6JRWK=
CP67-MEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrKSpR7UUN3ME2wMlA3QDFizszN M{jveXNCVkeHUh?=
DG-75 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fhS2lEPTB;MD6wOlg6QSEQvF2= MWnTRW5ITVJ?
LOXIMVI NIrmfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TXWWlEPTB;MD6wO|AzQCEQvF2= NV;aV5IxW0GQR1XS
HH NHf2WFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEexOVch|ryP MmX2V2FPT0WU
K5 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTveGNPUUN3ME2wMlA4OjJ4IN88US=> NHTMdmdUSU6JRWK=
EC-GI-10 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTBwMEeyOVch|ryP MlG0V2FPT0WU
SK-N-DZ NYDTVnZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3XU3dpUUN3ME2wMlA4OzB5IN88US=> NFG3e2FUSU6JRWK=
A3-KAW M3m0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jKNGlEPTB;MD6wO|M2OSEQvF2= NWTSZ3M{W0GQR1XS
MLMA NGLJZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;KTWM2OD1yLkC3OFY2KM7:TR?= MlH2V2FPT0WU
LB996-RCC MnTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfoTWM2OD1yLkC3O|A4KM7:TR?= M3jZSHNCVkeHUh?=
OS-RC-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PPd2lEPTB;MD6wO|c1QCEQvF2= NE[2O5NUSU6JRWK=
CTB-1 M1zndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jxPGlEPTB;MD6wO|gyKM7:TR?= M1TCNnNCVkeHUh?=
IST-MES1 MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDndWFDUUN3ME2wMlA4QTF{IN88US=> NUi1RXAxW0GQR1XS
LS-1034 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXiOVFKSzVyPUCuNFgxOzVizszN Mo\UV2FPT0WU
HT NX\EO2FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwMEiwPFYh|ryP MlTXV2FPT0WU
NCI-H2141 NXK3Nm1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL4foVEUUN3ME2wMlA5OSEQvF2= NFvX[ohUSU6JRWK=
LB2518-MEL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEixOFEh|ryP MnXXV2FPT0WU
GI-ME-N M{jD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfDNGR3UUN3ME2wMlA5PDV{IN88US=> M4PifHNCVkeHUh?=
TGW MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXXOpF1UUN3ME2wMlA5PjB5IN88US=> MWrTRW5ITVJ?
SK-NEP-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\pTWM2OD1yLkC4OlQyKM7:TR?= NF7r[2pUSU6JRWK=
NOMO-1 NVj3d29GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTUTWM2OD1yLkC5Nlc2KM7:TR?= M1HBb3NCVkeHUh?=
ES6 NWraZ2d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYqwWHVOUUN3ME2wMlA6PTh7IN88US=> NYHPRVZyW0GQR1XS
NCI-H209 MmPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfGTWM2OD1yLkC5O|g3KM7:TR?= MWDTRW5ITVJ?
GAK MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwMUCxOkDPxE1? MUfTRW5ITVJ?
BC-1 NFTNdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:1bnNlUUN3ME2wMlExOzZzIN88US=> NX;ETnZ1W0GQR1XS
KLE M4PzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r0RWlEPTB;MD6xNFQ1OyEQvF2= Ml;rV2FPT0WU
EW-3 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;pUHlCUUN3ME2wMlExQThizszN NGrWVG1USU6JRWK=
NKM-1 NWHEbVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrWeI5MUUN3ME2wMlEyOSEQvF2= NI\K[2hUSU6JRWK=
D-336MG NVnEdJdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zibmlEPTB;MD6xNVI1PCEQvF2= MlvIV2FPT0WU
NB69 NVnjNpdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO3NFZxUUN3ME2wMlEyOzBzIN88US=> NVTVfGpYW0GQR1XS
D-263MG M1HsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTveYJmUUN3ME2wMlEyPzF{IN88US=> MkTtV2FPT0WU
KP-N-YS MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnFOY9KSzVyPUCuNVIzQTFizszN NGKxdFlUSU6JRWK=
NCI-H1155 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL0TWM2OD1yLkGyOVU5KM7:TR?= NULMe3BmW0GQR1XS
BOKU MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMUK1O|kh|ryP MXrTRW5ITVJ?
LAMA-84 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTBwMUK5PUDPxE1? NYK1[3VTW0GQR1XS
Raji Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\JbZlRUUN3ME2wMlE{OTF5IN88US=> NHTTU3JUSU6JRWK=
LU-65 NFXhSYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jo[2lEPTB;MD6xN|MxPyEQvF2= NY\aeXREW0GQR1XS
NCI-H187 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULmUXJkUUN3ME2wMlE{QTJ2IN88US=> M{\hb3NCVkeHUh?=
GCIY MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlizTWM2OD1yLkG0PVAyKM7:TR?= NHXvW|ZUSU6JRWK=
NCI-H2107 Ml;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nyVWlEPTB;MD6xOVA5KM7:TR?= MlHKV2FPT0WU
NCI-H1522 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\1TWM2OD1yLkG1NlY3KM7:TR?= M{jCTnNCVkeHUh?=
NB6 M32wdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\5S2lEPTB;MD6xOVYzOyEQvF2= NVK3PVdEW0GQR1XS
EM-2 NF:3bHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjHTWM2OD1yLkG1O|A3KM7:TR?= MYnTRW5ITVJ?
HCC2218 NVHNe41TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfyb2VKSzVyPUCuNVU6QCEQvF2= M1fYNHNCVkeHUh?=
NCI-H748 NFTMOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfUTWM2OD1yLkG2N|c3KM7:TR?= NIfHR49USU6JRWK=
MS-1 NE\PUJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrsPXl3UUN3ME2wMlE3PTN5IN88US=> MUHTRW5ITVJ?
NB5 NIq0dINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ficGlEPTB;MD6xOlU6PyEQvF2= NHjDenBUSU6JRWK=
OMC-1 NFT2XGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;zV2VnUUN3ME2wMlE3Pjh6IN88US=> NGnreZFUSU6JRWK=
NCI-H345 MlfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fQZmlEPTB;MD6xOlkzQCEQvF2= M4TPXXNCVkeHUh?=
L-428 MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TuN2lEPTB;MD6xOlk1PSEQvF2= NYDEeJV3W0GQR1XS
SCH MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fsXmlEPTB;MD6xPFY5PSEQvF2= Mn\sV2FPT0WU
NCI-H1417 NVSzO5EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\jfHJKSzVyPUCuNVkzOjdizszN MWrTRW5ITVJ?
COLO-320-HSR M1LGVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3BTWM2OD1yLkG5OVMzKM7:TR?= MnXYV2FPT0WU
BT-474 M{f2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[0SnFqUUN3ME2wMlIxQDl{IN88US=> NV7WW4NHW0GQR1XS
GDM-1 NYXENJRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:xWIk3UUN3ME2wMlIyQTdzIN88US=> MoT2V2FPT0WU
NCI-H2196 NETiSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMkKyN|Uh|ryP NIfnWHJUSU6JRWK=
KP-N-RT-BM-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj5TWM2OD1yLkKyN|Q6KM7:TR?= MXTTRW5ITVJ?
KNS-81-FD M3vWfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXxTWM2OD1yLkKyPVU5KM7:TR?= NGDRNnNUSU6JRWK=
COLO-668 M3rjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMkO2O|Uh|ryP MoLWV2FPT0WU
C2BBe1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY[wVXVyUUN3ME2wMlI3PzR5IN88US=> NUHRTVVkW0GQR1XS
Ramos-2G6-4C10 NGr0dpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;SXZZKSzVyPUCuNlY6PTRizszN Mn;qV2FPT0WU
CAS-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPaZpNjUUN3ME2wMlI4ODl4IN88US=> MkLrV2FPT0WU
GOTO M2i5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHmdI1SUUN3ME2wMlI4QDl2IN88US=> MYLTRW5ITVJ?
LP-1 NYPISJlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMkiwOVch|ryP NFHPRYJUSU6JRWK=
NCI-SNU-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfYS3FKSzVyPUCuNlk1OjJizszN NGO1NFlUSU6JRWK=
EB-3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1q5[WlEPTB;MD6yPVk4QSEQvF2= MkPEV2FPT0WU
MHH-NB-11 NWrJ[IFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS0TWM2OD1yLkOwOFAzKM7:TR?= MnjQV2FPT0WU
SK-N-FI NEnPPWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXuU45PUUN3ME2wMlMyPjl{IN88US=> MmjOV2FPT0WU
HCC2157 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwM{O5NVMh|ryP Mn[4V2FPT0WU
SIMA MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwM{S1PFEh|ryP MkHaV2FPT0WU
MDA-MB-134-VI MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrITWM2OD1yLkO2PVI5KM7:TR?= NGHiTGZUSU6JRWK=
NCI-H1694 MkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTBwM{eg{txO NETYW2hUSU6JRWK=
EHEB NGLZXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX4TWM2OD1yLkO5NFg2KM7:TR?= M2r6NnNCVkeHUh?=
U-266 M3zUZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwM{m4OFYh|ryP NH3nUJVUSU6JRWK=
LC-1F Mo\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC4eGlKSzVyPUCuOFM4PjVizszN MoTHV2FPT0WU
SHP-77 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwNEe4OVUh|ryP MkjPV2FPT0WU
LS-513 M1PqbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfPbGl6UUN3ME2wMlQ6OzB5IN88US=> MXTTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-ERK / ERK; 

PubMed: 20068074     


Paclitaxel pulse induces phospho-ERK. Paclitaxel (6ug/mL) was pulsed over 10min to 4hr prior to cell harvesting. A biphasic activation is observed in the resistant cells.

MARCKS (pSer159/163); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

Src (pTyr416); 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

p-JAK2 / p-STAT3 / p-AKT / p-MAPK / Bcl-xl / MCL-1; 

PubMed: 29849942     


OVCAR-8 and MDAH2774 cells were treated with ruxolitinib (20 μM), paclitaxel (10 nM) or the combination for 24 h. Whole cells were collected and determined for the change of STAT3, AKT and ERK pathways and expression of BCL-XL and MCL-1 by Western blot.

Id1; 

PubMed: 25344919     


(A) Paclitaxel suppressed Id1 expression in H520 cells in a time-dependent manner.

MARCKS; 

PubMed: 26015406     


Paclitaxel treatment induces activation of MARCKS and Src in TNBC cells. Cells were incubated with various doses of paclitaxel as indicated. After 24 hours, cells were collected and subjected to Western blot analysis.

20068074 26015406 29849942 25344919
Growth inhibition assay
Cell viability; 

PubMed: 28823711     


Paclitaxel reduces HeyA8 tumor cell viability in MTT assay.

28823711
Immunofluorescence
α-tubulin; 

PubMed: 22904633     


Cellular α-tubulin (red) was blotted by immunostaining and subsequent confocal microscopy 3 hours after A549 cells were treated with 12.5 nM of paclitaxel and 12.5 nM of PLGA-PEI-TAX, respectively. The same experiment was performed with 62.5 nM of paclitaxel and 62.5 nM of PLGA-PEI-TAX in A549/T12 cells. PLGA-PEI-TAX, poly(lactic-co-glycolic acid)-polyethylenimine nanoparticles loaded with paclitaxel.

Rab11a/BV9; 

PubMed: 29290815     


Paclitaxel reversed the DAVLBH-mediated inhibition of internalized VE-cadherin recycling back to the cell membrane. HUVECs pretreated with or without paclitaxel were treated with or without DAVLBH for 4 h. Quantification of BV9/Rab11a colocalization is shown (n = 3).

22904633 29290815
In vivo

The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively. [4]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs
  • Concentrations: 0.1-100 pM
  • Incubation Time: 72 hours
  • Method:

    Cells including human neonatal dermal microvascular ECs (HMVECs), human umbilical vein ECs (HUVECs), human umbilical artery ECs (HUAVECs), normal human astrocytes (NHAs), normal human dermal fibroblasts (NHDFs), normal human epidermal keratinocytes (NHEKs), human mammary epithelial cells (HMEpCs), human prostate epithelial cells (PrEpCs) and human umbilical artery smooth muscle cells (UASMCs) are cultured. Cell proliferations are performed in 96-well plates using cells between passages 6 and 12. Cells are seeded at 3000–5000 cells/well and allowed to attach for 4 hours. Paclitaxel, diluted in culture medium, is added in quadruplicate wells and the cells ae incubated for 3 days before MTS reagents are added to quantitate the live cells in each well.


    (Only for Reference)
Animal Research:

[4]

- Collapse
  • Animal Models: Female, 20-22 g homozygous nude athymic mice with BC-V and BC-ER tumors
  • Dosages: 20 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 171 mg/mL (200.25 mM)
Water Insoluble
Ethanol ''18 mg/mL
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 853.91
Formula

C47H51NO14

CAS No. 33069-62-4
Storage powder
in solvent
Synonyms NSC 125973, PTX, Taxol, Onxal
Smiles CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04252768 Not yet recruiting Drug: Eftilagimod Alpha|Drug: Paclitaxel Metastatic Breast Cancer Immutep S.A. June 2021 Phase 1
NCT04526470 Not yet recruiting Drug: Alpelisib + Paclitaxel Solid Tumor|Stomach Cancer Seoul National University Bundang Hospital September 1 2020 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • Answer:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • Question 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • Answer:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Tags: buy Paclitaxel | Paclitaxel supplier | purchase Paclitaxel | Paclitaxel cost | Paclitaxel manufacturer | order Paclitaxel | Paclitaxel distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID